GHRP-6

Growth hormone secretagogue · Also known as Growth Hormone Releasing Peptide-6, Growth Hormone Releasing Hexapeptide, GHRP6

What is ghrp-6?

A synthetic hexapeptide that stimulates the pituitary gland to release growth hormone by activating the ghrelin receptor (GHS-R1a). It produces strong GH pulses along with a notable increase in appetite, making it distinct from more selective secretagogues like ipamorelin.

GHRP-6 was one of the first growth hormone secretagogues developed, emerging from research in the 1980s and 1990s on synthetic met-enkephalin analogs. It helped establish the ghrelin receptor pathway as a target for GH stimulation and paved the way for newer, more selective peptides. Clinical pharmacokinetic studies in healthy volunteers have confirmed its safety profile and GH-releasing potency.

Key takeaway: GHRP-6 is a potent growth hormone secretagogue with solid clinical evidence for GH release, though its strong appetite stimulation and cortisol/prolactin elevation at higher doses make it less selective than newer alternatives like ipamorelin.

Benefits & evidence

Growth hormone release High confidence
Muscle growth support Moderate confidence
Appetite stimulation High confidence
Improved recovery Moderate confidence
Cardioprotection Preliminary confidence

How it works

GHRP-6 binds to the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by the body's natural hunger hormone ghrelin. This triggers a signaling cascade involving protein kinase C and calcium mobilization (independent of the cAMP pathway used by GHRH), resulting in a powerful pulse of growth hormone from the pituitary. The effect is amplified when combined with endogenous GHRH.

Because GHRP-6 activates the ghrelin receptor, it also stimulates appetite centers in the hypothalamus, producing noticeable hunger within 15 to 30 minutes of injection. It additionally causes modest, transient increases in cortisol and prolactin at doses above 100 mcg. The distribution half-life is about 8 minutes with an elimination half-life of roughly 2.5 hours, so multiple daily doses are needed to sustain elevated GH output.

Dosing information

Typical dosing protocol
Starting dose

100 mcg 2x/day

Weeks 1-4
Maintenance dose

100 mcg 2-3x/day

8-12 week cycles

Administered subcutaneously on an empty stomach (at least 30 minutes before food). 100 mcg is near the saturation dose for maximal GH release per injection. Doses above 100 mcg increase cortisol and prolactin elevation without proportionally greater GH output. Based on clinical pharmacokinetic studies in healthy volunteers.

Side effects

Most side effects tend to improve as your body adjusts.

Intense hunger Common
Water retention Common
Injection site irritation Common
Cortisol elevation (at higher doses) Moderate
Prolactin elevation (at higher doses) Moderate
Lightheadedness Uncommon

Research (10 studies)